Open Access

Magnesium sulfate treatment for juvenile ferrets following induction of hydrocephalus with kaolin

  • Domenico L. Di Curzio1, 2,
  • Emily Turner-Brannen2,
  • Xiaoyan Mao2 and
  • Marc R. Del Bigio2, 3Email author
Fluids and Barriers of the CNS201613:7

https://doi.org/10.1186/s12987-016-0031-4

Received: 13 January 2016

Accepted: 6 April 2016

Published: 27 April 2016

Abstract

Background

Previous work with 3-week hydrocephalic rats showed that white matter damage could be reduced by the calcium channel antagonist magnesium sulfate (MgSO4). We hypothesized that MgSO4 therapy would improve outcomes in ferrets with hydrocephalus induced with kaolin at 15 days.

Methods

MRI was performed at 29 days to assess ventricle size and stratify ferrets to treatment conditions. Beginning at 31 days age, they were treated daily for 14 days with MgSO4 (9 mM/kg/day) or sham saline therapy, and then imaged again before sacrifice. Behavior was examined thrice weekly. Histological and biochemical ELISA and myelin enzyme activity assays were performed at 46 days age.

Results

Hydrocephalic ferrets exhibited some differences in weight and behavior between treatment groups. Those receiving MgSO4 weighed less, were more lethargic, and displayed reduced activity compared to those receiving saline injections. Hydrocephalic ferrets developed ventriculomegaly, which was not modified by MgSO4 treatment. Histological examination showed destruction of periventricular white matter. Glial fibrillary acidic protein content, myelin basic protein content, and myelin enzyme activity did not differ significantly between treatment groups.

Conclusion

The hydrocephalus-associated disturbances in juvenile ferret brains are not ameliorated by MgSO4 treatment, and lethargy is a significant side effect.

Keywords

Hydrocephalus Ferret Kaolin Magnesium sulfate Brain

Background

Hydrocephalus is a common neurological condition where cerebrospinal fluid (CSF) flow dynamics are altered, leading to enlargement of ventricular cavities in the brain. The histopathologic consequences of hydrocephalus depend on the age of onset, rate of ventricular enlargement, and the etiology [1]. The brain damage induced by hydrocephalus is multifactorial with mechanical factors leading to primary destruction of periventricular axons due to gradual physical stretching and compression, accumulation of metabolic waste products in the CSF, and ischemic changes causing decreased white matter blood flow that contributes to axonal and oligodendroglial damage [2, 3]. Elevated calcium (Ca2+) coincides with increased white matter content of calpain I, along with heightened immunoreactivity in periventricular axons exhibited by young hydrocephalic rats with appreciable axonal damage, which suggest that calcium-mediated proteolysis may be associated with axonal cytoskeletal damage found in hydrocephalus [4].

Magnesium (Mg2+) is a calcium channel antagonist; extracellular Mg2+ antagonizes Ca2+ influx by blocking voltage and receptor-mediated calcium channels along with NMDA channel receptors in a voltage-dependent manner [5, 6]. Intracellular Mg2+ is regulated by at least five distinct transporters [7]. Peripherally administered Mg2+ enters brain tissue of rabbits and cats, albeit to a lesser magnitude than muscle [8]. Magnesium sulfate (MgSO4) administration by bolus or short-term infusion (e.g. 3 days) has shown short-term (hours to <7 days) outcome improvements in animal models of experimental spinal cord injury [9], reversible focal cerebral ischemia [10], kainate induced neuron degeneration [11], hypoxic-ischemic brain damage [12, 13], and traumatic brain injury [1416]. Few experiments have looked at longer-term benefits of magnesium. A bolus of magnesium chloride after fluid percussion brain injury in adult rats was associated with improved motor outcome at 4 weeks [17].

Clinically, MgSO4 has been used to suppress uterine contractions during premature labor and to reduce convulsions in pregnant women with preeclampsia [18]. In these circumstances, there is an association between maternal receipt of MgSO4 and reduced risk of cerebral palsy in the offspring; this suggests that it could be neuroprotective in preterm birth although the benefit in term birth is much less clear [19, 20]. In infants with hypoxic-ischemic encephalopathy, the composite results of five clinical trials indicate a significant reduction in the unfavorable short-term outcome but a trend to increased mortality overall [21]. If effective, its protective mechanism remains unclear. MgSO4 is a vasodilator that might improve cerebral circulation [22]. It can also reduce monocyte-mediated proinflammatory cytokine production and increase intracellular magnesium levels, which may be beneficial in decreasing inflammation [23].

Pharmacologic intervention might be a useful supplement to surgical shunts for the management of hydrocephalus [24]. We previously showed that MgSO4 was beneficial in hydrocephalic rats [25]. Three-week old rats received kaolin injections into the cisterna magna to induce hydrocephalus; after 2 weeks, they were treated with parenteral administration of MgSO4 for 2 more weeks. There was reduced reactive astrogliosis in the frontal cerebrum and improved gait performance on an accelerating rotating cylinder task. Despite these benefits, research with rodents is limiting because they have a small volume of white matter, which is the main region of damage in human brains. Moreover, stroke research has provided a valuable lesson in the major setbacks that can occur when basing clinical treatment on the success of pharmacological studies with rodents; this has prompted the necessity of preclinical treatment efficacy in gyrencephalic brains before proceeding to human trials [26]. Thus, we developed a model of hydrocephalus in 2-week old ferrets using injection of kaolin (aluminum silicate) into the cisterna magna, and we showed similarities to other animal models and the human condition [27]. Ferrets are born with relatively immature brains which develop a complex gyrencephalic morphology that has been studied extensively [28, 29]; consequently they are useful for modeling the neurologic disorders of human fetuses and infants [30]. Our overall goal is to develop a pharmacologic intervention that could be used to mitigate brain damage in the period prior to definitive shunt therapy. We hypothesized that MgSO4 treatment would lead to behavioral, structural, and/or biochemical improvements in juvenile ferrets with experimental kaolin-induced hydrocephalus.

Methods

Animals

Twenty pigmented sable ferret kits (n = 13 males and n = 7 females) were obtained from Marshall Farms (North Rose, NY) at postnatal day 7 (P7) in 4 l along with their mothers (jills). The kits stayed with their mothers in enclosed cages until P46. The cages were located in a room kept on a 12:12 h (6 a.m.–6 p.m.) light–dark cycle, and the room temperature and relative humidity were 21–22 °C and ~35–45 %, respectively. Food and water were provided ad libitum; the kits started eating solid food around P30. For identification, tattoos were imprinted on their paws. All animals were treated humanely according to the guidelines set forth by the Canadian Council on Animal Care. The institutional animal ethics committee approved the experimental protocols (protocol #11-012). All efforts were made to minimize the number of animals used and ensure the least amount of suffering experienced.

Hydrocephalus induction

Hydrocephalus was induced using kaolin (aluminum silicate; Sigma, St. Louis MO) as described previously [27]. Briefly, kaolin injections were performed on all 4 litters at P15 (5 per litter—total n = 20; weight 69–93 g). They were anesthetized using 2.5 % isoflurane in oxygen, and the dorsum of their necks were shaved and cleansed. Using a 27-gauge needle, 0.2 mL of 20 % sterile kaolin suspension (250 mg/mL in 0.9 % saline) was injected percutaneously into the cisterna magna under aseptic conditions. Animals were monitored during recovery and observed for signs of discomfort and/or neurological impairment and then were otherwise returned to their mothers. Subcutaneous (sc) injections of buprenorphine (0.03 mg/kg) and sterile 0.45 % saline were given every 12 h for 2 days to decrease potential pain and possible dehydration, respectively. They were weighed daily, and those experiencing severe neurologic impairment or weight loss were sacrificed to cease further suffering.

Magnetic resonance imaging and assignment to treatment groups

The T2-weighted MR images of the brain were obtained using with a 7 Tesla Bruker Biospec/3 MR scanner (Karlsruhe, Germany) as previously described [27]. The first images were attained 2 days post kaolin injections at P17 to confirm successful hydrocephalus induction with kaolin, and then 14 days post kaolin at P29 to examine ventricle size and stratify treatment groups. The areas of the lateral ventricles to cerebrum brain area, third ventricle width to cerebrum width, cerebral aqueduct area to midbrain area, and fourth ventricle area to hindbrain area ratios were measured as previously described [27]. Ferrets were stratified based on ventricle size and assigned listwise to saline (0.9 % NaCl) and MgSO4 treatment groups. A third set of MR images was taken after the 14-day drug treatment period at P45, no more than 24 h before euthanasia, to assess ventricle size again.

Drug preparation and administration

The MgSO4 and/or NaCl treatments were administered starting 16 days post-kaolin at P31 (n = 8 for MgSO4 and n = 8 for NaCl). All animals were weighed daily, and their weights were used to calculate treatment volumes. Stock solutions of 1.0 M MgSO4 and 0.9 M NaCl were prepared in distilled H2O at room temperature and stored at 4 °C; the solutions were labeled A and B, and treatments were given blindly based upon a volume drug to body weight formula. They received either a ~9 mM/kg/day dosage of MgSO4 or NaCl daily for 14 days, which were administered by sc injections given 3 times per day on weekdays (~3 mM/kg/dose) and 2 times per day on weekends (~4.5 mM/kg/dose) to ensure that all animals received the entire dosage. This calculated dosage was derived from testing different MgSO4 concentrations with rodents in a previous study, where 8.2 mM/kg/day was found to be protective [25]. The ferrets received their first injection in the morning before behavioral testing. Their second daily injection was given in the late afternoon, and the third injection was administered near midnight to maintain trough levels. Because of the expense, we could not conduct a dose-escalation study.

Behavioral testing

Previous work with kaolin-induced hydrocephalic ferrets [27] showed that they differed from controls in a limited number of the behavioral tests previously studied [31]; these were chosen for the current study. Behavioral testing commenced at P10-11 and continued 3 times weekly until P43-44 for all kits (n = 16). Behavior tests were conducted prior to the daily drug administration to minimize the effect of lethargy in the MgSO4 recipients. The kits were not exposed to the test situations prior to testing. Open field behavior was assessed using two apparatuses. The first chamber was an enclosed square (44 × 43 × 29 cm) with 15 light beam sensors on each axis to quantitate ambulatory, vertical, and total movements (Opto-Varimex 3; Columbus Instruments International Corp., Columbus, OH, USA). Animals were observed individually for 3 min and tested once per session. The second chamber was a 75 × 75 × 45 cm transparent plastic square, where the kits were videotaped, and motor performance was analyzed for 3 min using HVS Image 2100 Plus Tracking System software (HVS Image Ltd, Twickenham, Middlesex, UK). Quantitative measures were performed after dividing the chamber into 100 (7.5 × 7.5 cm) squares and included the length of path traversed and the number and percent of squares entered. Qualitative observations were also recorded in the second chamber for pivoting, crawling, walking, running, and rearing.

Sacrifice and brain dissection

Ferrets were euthanized within 24 h of final MRI using isoflurane anesthesia (5 %) followed by carbon dioxide (CO2) narcosis and exsanguination by transcardiac perfusion at ~P46 or when humane endpoints were met as described previously [27]. Ferret brains were rapidly removed, photographed, and then split in the parasagittal plane 1 mm from the midline. The right hemisphere was dissected into anterior frontal lobe, dorsal frontal cerebrum, and dorsal parietal cerebrum, which were frozen in liquid nitrogen (N2) and stored at −70 °C. The left hemisphere was immersion fixed in cold 3 % buffered paraformaldehyde for several days; then it was sliced in the coronal plane, dehydrated, and embedded in paraffin wax.

Histology and immunohistochemistry

All paraffin blocks were sectioned coronally (6 μm thickness) and stained with hematoxylin and eosin (H and E). The cerebrum at the level of the anterior horn of the lateral ventricles was stained with solochrome cyanine and counterstained with eosin for visualization of myelin. Sections were immunostained with rabbit polyclonal anti-glial fibrillary acidic protein (GFAP; 1:10,000 dilution; DAKO Z0334; Glostrup, Denmark) to label astrocytes and reactive astrocytes. The primary antibody underwent 1.5 h incubation at room temperature. This was followed by incubation with appropriate biotinylated secondary antibody, followed by reaction with streptavidin-peroxidase, detection with diaminobenzidine (DAB, Sigma D5905), and finally counterstaining with hematoxylin. Negative controls were treated without the primary antibody. Corpus callosum thickness was measured using 100× ocular magnification at the sagittal midline and above the lateral angle of the anterior horn of the lateral ventricle. The second site was chosen because fragmentation of the midline region in some hydrocephalic brains preventing proper measurement of corpus callosum thickness. For comparative purposes, non-hydrocephalic ferrets from our previous experiment [27] were also examined.

Myelin enzymes and enzyme-linked immunosorbent assays

Frozen dorsal frontal and parietal cerebrum samples were homogenized using a radio immunoprecipitation assay (RIPA) buffer including protease inhibitors phenylmethylsulfonyl fluoride (PMSF) and aprotinin, which likely explain the lower myelin enzyme activities than were obtained previously [27]. Total protein quantification was determined with the Micro BCA (Pierce) Protein Assay kit (Thermo Scientific, Rockford, Illinois, USA). Dorsal frontal cerebrum homogenates were used to quantify myelin basic protein (MBP) and GFAP content by using ELISAs, as previously described in detail [27]. Colorimetric assays were performed in triplicate, and results are shown in μg of MBP or GFAP per gram of protein and averaged per sample. Dorsal parietal cerebrum samples were used to quantify the enzyme activity of UDP-galactose:ceramide galactosyltransferase (CGalT) and glycerylphosphorylcholine phosphocholine phosphodiesterase (GPC-PP) using the artificial substrate p-nitrophenylphosphorylcholine (pNPP). Both are enzymes that are enriched in myelin. They were quantified in triplicate as described previously [32, 33].

Atomic absorption spectroscopy

Flame atomic absorption spectroscopy (FAAS) was performed to determine Mg levels in anterior forebrain samples as indicated previously [34] except for the following differences. Ferrets were given their last dose of MgSO4 or NaCl 35–152 min (mean 68.88 ± 13.46) before sacrifice. Forebrain samples were thawed and weighed then dissolved in 18 M sulfuric acid and 16 M nitric acid over gentle heat. Standards were prepared from a 1000 μg mL−1 Mg standard solution (Alfa Aesar 88077) at concentrations of 0.50, 0.40, and 0.20 μg mL−1, along with a 1 % nitric acid blank. Mg content was measured using Atomic Absorption Spectrometer AAnalyst 400 with a PerkinElmer Lamp (Intensitron) using a wavelength of 285.21 nm. Measurements were performed in triplicate and averaged to obtain concentrations (μg Mg2+ per gram brain tissue).

Statistical analysis

All data are presented as mean ± SEM, unless otherwise indicated. Quantitative data were analyzed to confirm a normal distribution, and p values ≤0.05 were considered statistically significant. Statistical analyses for the behavioral tasks, MRI, and all biochemical analyses were conducted with the juvenile ferrets (n = 15). Data were assessed using ANOVA and two-tailed t-tests for behavioral testing, ventricle size, histological data, and biochemical assays to compare MgSO4 and NaCl hydrocephalic treatment groups. Qualitative assessments for motor and behavioral development were analyzed separately from quantitative measures. Statistical analyses were conducted using the SPSS 19.0 software program.

Results

Mortality

Of the 20 kaolin-injected juvenile ferrets, three were euthanized due to severe neurological deficits within the first 2 days post-injection (P16), one was euthanized on P22 due to severe weight loss and neurological impairment, and one was euthanized on P43 due to persistently low weight and neurological impairment despite only slight ventricle enlargement (this animal was initially assigned to receive MgSO4). Two of the remaining ferrets were nonhydrocephalic; these were used for comparative purposes only. The focus of the results is on the hydrocephalic ferrets (n = 13; 8 males and 5 females) that survived the 14-day drug therapy period. All were euthanized within 24 h of the final MRI between postnatal days P45–P46.

Ventricle size on magnetic resonance imaging

Ventricular expansion was noticeable 2 days after kaolin injections, where the lateral ventricles were already significantly larger compared to the nonhydrocephalic animals (p < 0.010, t test). From this time onward, the hydrocephalic ferrets displayed enhanced signal in the periventricular white matter on the T2-weighted MR images indicating elevated water content. At 14 days post-kaolin injections (P29), MR images showed a range of ventriculomegaly in the hydrocephalic ferrets (Fig. 1). This was particularly evident in the lateral and third ventricles, which were significantly enlarged (both p < 0.05, t tests). Ferrets were stratified according to ventricle size and alternately assigned to MgSO4 or NaCl treatment groups to ensure that there was no significant difference between hydrocephalic groups before therapy. Both hydrocephalic groups displayed further expansion of the ventricles during the therapeutic period, exhibiting significant progressive enlargement of the lateral (Fig. 2; Table 1) and third ventricles (all p < 0.05, t tests). Comparison of the NaCl- and MgSO4-treated ferrets showed no significant differences for any of the ventricle regions (all p > 0.05, t tests; Table 1).
Fig. 1

T2-weighted magnetic resonance images showing frontal coronal slices of brains of ferrets without hydrocephalus as well as ferrets that were treated with MgSO4 or NaCl between 29 and 45 days age. Progressive ventriculomegaly is evident in these examples of both treatments

Fig. 2

Box plots (mean ± standard error of mean) showing cross sectional ratio of the lateral ventricle frontal horn areas to the cerebrum on the magnetic resonance images. The 16-day images were obtained 2 days after kaolin injection, the 29-day images were 14 days after kaolin injection and immediately prior to onset of drug treatment, and the 45-day images were obtained at the end of the treatment period shortly prior to termination (n = 7 for NaCl and n = 6 for MgSO4 each at all time points). In comparison to non-hydrocephalic controls (not shown) and previous time points the ventricles enlarged progressively at successive time points (p < 0.05). There were no significant differences between the MgSO4 and NaCl treatment groups

Table 1

Results of magnesium sulfate treatment on hydrocephalic ferrets

 

Non-hydrocephalic controls

NaCl-treated hydrocephalus

MgSO4-treated hydrocephalus

Sample size

2

7

6

Lateral ventricle area index (P29/pre-treat)

0.012 ± 0.002

0.147 ± 0.024*

0.155 ± 0.023*

Lateral ventricle area index (P45/post-treat)

0.006 ± 0.0005

0.219 ± 0.053*#

0.254 ± 0.046*#

Percent enlargement ventricles during treatment

48.9 ± 23.1

63.9 ± 24.4

Body weight (g) (P29/pre-treat)

148.0 ± 8.0

114.3 ± 4.8*

106.8 ± 9.1*

Body weight (g) (P45/post-treat)

264.5 ± 34.5#

288.3 ± 12.8#

170.0 ± 31.0*@#

Rearing activity (beam breaks per 3 min) (P43/post-treat)

71 ± 16

57 ± 15

22 ± 20*

Ambulatory activity (beam breaks per 3 min) (P43/post-treat)

541 ± 21

460 ± 44

321 ± 71*

Total activity (beam breaks per 3 min) (P43/post-treat)

684 ± 20

584 ± 54

443 ± 89*

Number cells entered—open field (per 3 min) (P43/post-treat)

88 ± 7

115 ± 12

111 ± 15

Distance traveled—open field (m per 3 min) (P43/post-treat)

5.64 ± 0.39

7.58 ± 0.95

7.11 ± 1.08

Medial corpus callosum thickness (μm)

965 ± 95

410 ± 71*

315 ± 97*

Lateral corpus callosum thickness (μm)

665 ± 45

330 ± 50*

245 ± 59*

MBP content frontal cerebrum (μg MBP/g protein)

72.19 ± 12.75

64.25 ± 19.66

56.07 ± 14.15

CGalT activity parietal cerebrum (nM/mg protein/h)

0.029 ± 0.008

0.075 ± 0.024

0.051 ± 0.014

GPC-PP activity parietal cerebrum (nM/mg protein/h)

15.25 ± 1.83

14.42 ± 0.90

11.64 ± 1.20

GFAP content frontal cerebrum (μg GFAP/g protein)

0.64 ± 0.02

0.90 ± 0.13

0.70 ± 0.12

Frontal cerebrum magnesium (μg Mg2+/g brain tissue)

133.64 ± 4.97

135.59 ± 10.37

150.89 ± 5.23

All data are presented as mean ± SEM. Behavior and ventricle size are specified at by postnatal day (P) age. All brain structural and biochemical data are at P46

CGalT ceramide galactosyltransferase

GFAP glial fibrillary acidic protein

GPC-PP glycerylphosphorylcholine phosphocholine phosphodiesterase

MBP myelin basic protein

* p < 0.05 control vs. hydrocephalic, t tests or ANOVA

@ p < 0.05 NaCl vs. MgSO4-treated ferrets, t tests or ANOVA

# p < 0.05 P29 (pre-treat) vs. P45 (post-treat), t tests

Body weight and behavioral assessments

Behavioral testing began at P10–11 to determine baseline performance before kaolin injection was performed at P15. Successful induction of hydrocephalus was typically associated with weight loss for several days following injection. Overall, the hydrocephalic ferrets weighed 39 % less than nonhydrocephalic ferrets at P21 (p < 0.001, t test) and 25 % less at P28 (p = 0.009, t test). After the 14-day treatment period, the MgSO4-treated hydrocephalic ferrets weighed significantly less than the NaCl hydrocephalic group during and after treatment (all p < 0.05, ANOVA; Table 1).

By the end of the pretreatment period (P28–P30), all the ferrets were crawling, similar to previously assessed motor development [27]. Walking commenced on P34–37, with no appreciable differences between hydrocephalic groups. Qualitatively, both groups reached motor and behavioral developmental milestones at the same time, although several of the MgSO4-treated hydrocephalic ferrets (n = 5) were more unsteady and engaged in less exploratory behavior. Unlike our previous finding [27], the hydrocephalic ferrets did not become hyperactive or wander in circles within the enclosure. MgSO4-treated ferrets were more lethargic than NaCl-treated animals. Quantitative activity measurements showed that the hydrocephalic MgSO4 group displayed significantly less ambulatory movement, fewer cell entries, less distance traveled overall, and less supported rearing, compared to the NaCl group during the first week of treatment (all p < 0.05, ANOVA; data not shown). These between-group discrepancies were evident primarily during transition to walking phase of development but dissipated by the last behavioral time point measured and were not significantly different post-treatment (Table 1).

Structural and biochemical changes in brain

Macrophages that had engulfed kaolin and associated collagen deposition were microscopically identified throughout the basal subarachnoid space, having spread from the cisterna magna injection site; only rare macrophages were present in the fourth ventricle. Ventriculomegaly was accompanied by cerebral thinning surrounding the lateral ventricles and decreased depth of cerebral sulci. Intact white matter structures such as the internal capsule showed equivalent myelin staining in hydrocephalic and non-hydrocephalic ferrets. There was thinning and fraying of the periventricular white matter in all hydrocephalic ferrets; these damaged regions had no myelin staining. The corpus callosum thickness did not differ between the MgSO4 and NaCl treatment groups (Fig. 3; Table 1). In comparison to non-hydrocephalic ferrets, there was a slight but not statistically significant reduction of cerebral MBP content in the hydrocephalic ferrets; however, there was no difference between treatment groups (Table 1). To determine if the severity of ventriculomegaly had any impact on the MBP content, both treatment groups were subdivided into moderate and severe hydrocephalus. Subgroup analyses of the 4 most severely affected ferrets in each group showed no significant differences between groups (data not shown). It should be noted that the MBP content at P46 is just beginning the rapid accumulation phase [27]; this is comparable to human brain shortly after full term gestation.
Fig. 3

Photomicrographs showing white matter above the frontal horn of the lateral ventricle in 46-day-old hydrocephalic ferret brains, after a 14-day treatment period with MgSO4 or NaCl. a (upper pair)—corpus callosum CC thinning is evident in both animals (solochrome cyanine stains myelin blue, with pink eosin counterstain). b (lower pair)—GFAP immunolabeling (brown) showing hypertrophic reactive astrocytes in periventricular white matter near the lateral angle of the frontal horn. There is no obvious difference between the two groups of hydrocephalic ferrets. Objective magnification: a-40x, b-100x; Scale bar = 100 μm. Lateral ventricles LV, Subventricular zone SVZ

In periventricular and perivascular foci of the white matter adjacent to the frontal horns of the lateral ventricles, NaCl and MgSO4-treated hydrocephalic ferrets displayed similar GFAP immunostaining of hypertrophic astrocytes (Fig. 3). ELISA analysis of GFAP content was 27 % lower in the MgSO4 hydrocephalic group compared to NaCl group, but the difference was not statistically significant (p = 0.375, ANOVA; Table 1). Subgroup analysis of the most severely affected ferrets also did not reveal significant differences in GFAP content between treatment groups (data not shown).

Myelin enzyme activity was measured in hydrocephalic ferret brains. CGalT is active in oligodendrocytes during myelin production [35]; we previously showed highest activity from P35–P56 [27]. There were no significant differences between hydrocephalic treatment groups (Table 1). GPC-PP is abundant in mature myelin [36]; we previously showed that the activity began to increase at P35 [27]. Compared to the untreated hydrocephalic ferrets, the MgSO4 group tended to show lower GPC-PP activity than the NaCl group (p = 0.056) (Table 1), but subgroup analysis still did not reach significance (data not shown).

Mg2+ in anterior forebrain samples was slightly, but not significantly, higher in the MgSO4 group compared to the NaCl-treated group (p = 0.38, t test) (Table 1).

Discussion

Mg2+ was shown to have mild protective benefits in rats with experimental hydrocephalus treated from 5 to 7 weeks age but not in rats treated from 1 to 3 weeks age [25, 34]. We had hoped that MgSO4 treatment would also yield therapeutic benefits in young hydrocephalic ferrets. As has been recommended for preclinical stroke and brain trauma studies [26, 37], the experimental design included randomization, blinding, and multiple outcome measures. However, in comparison to NaCl-treated hydrocephalic ferrets, we did not find any behavioral, histological, or biochemical evidence to support the hypothesis that MgSO4 therapy, at the same dose that was effective in rats, benefits hydrocephalic ferrets. Treated ferrets had transient sedation, which is well-documented [38], impaired weight gain, and tendency to greater progression of ventriculomegaly. Despite more severely enlarged ventricles, MgSO4 treatment was associated with reduced GFAP accumulation in ferrets albeit not significantly; this finding is similar to that seen in hydrocephalic rats treated from 5 to 7 weeks age [25]. Reduced astroglial reaction has also been reported in kaolin-induced and congenitally hydrocephalic H-Tx rats treated with minocycline or decorin [3941]. Although reduced GFAP accumulation is often considered an indicator of benefit, another possibility is that Mg2+, which blocks signaling between astrocytes [42], simply masks the astrocytic response to brain damage.

Why was MgSO4 therapy unsuccessful in hydrocephalic ferrets? Rationale for the experiment was based upon a previously-demonstrated neuroprotective effect in juvenile hydrocephalic rats and a range of experimental data from other neurological disorders. Technical and design aspects must be considered. It remains unclear whether entry of Mg2+ into brain is via the choroid plexus and CSF or through the blood brain barrier [43, 44], although the observed side effect of sedation indicates entry into the brain [8, 45, 46]. Lethargy is a potential confounder in the behavioral assessments, and it prevented complete blinding of the investigators. More importantly, weight gain was retarded in the MgSO4 treated ferrets, possibly because lethargy impaired feeding or because of the effect of Mg2+ on intestinal smooth muscle [7]. Undernutrition might have had a negative effect on the outcome. This might be overcome experimentally by using a matched feeding strategy. Unfortunately, ferrets are obligate carnivores with short intestinal tracts; they can require special diets when they are ill [47], and therefore might not be the ideal animal for studies where feeding is compromised. Periodic subcutaneous injections would result in troughs and peaks; in rats Mg2+ levels peak at approximately 2 h and return to normal levels within 4 h after injection [25]. We had considered using osmotic minipumps, but none would accommodate sufficiently large volumes for the treatment period nor could they adjust for the increasing weight of the maturing ferrets. Furthermore, based on discussions with the veterinarians, the potential complications (maternal biting of the surgical site and sloughing of the skin over the minipumps) outweighed the potential benefits. During the treatment period, we did observe that the MgSO4-treated ferrets experienced some skin irritation at the injection sites; rotating the locations of the injections minimized this. Oral administration potentially provides longer periods of exposure; however, peak levels are not as high as those that follow parenteral administration [48]. We also observed that some MgSO4-treated ferrets began gagging and/or vomiting immediately after injections, which would have made repeated gavage difficult. In a clinical situation, tube feeding would negate this confounder. Perhaps the intervention was timed incorrectly. If the ventricular enlargement is too mild a therapeutic benefit might be difficult to detect or if the intervention is too late, no benefit might be possible. However, subgroup analysis of the 4 most severely affected ferrets in each group as well as the least severely affected still showed no significant differences between treatment groups.

We must also consider that the rodent experimental studies considered in the Introduction do not translate to larger animals. The majority documented only short-term benefit. In short term studies of brain hypoxic-ischemic damage in immature rat, sheep, and pig models, MgSO4 has had inconsistent outcomes and results have been confounded by mild hypothermia; for this condition reviewers concluded “peripherally administered MgSO4 is unlikely to be neuroprotective” [49]. A meta-analysis of 8 randomized controlled trials with a total of 786 head-injured patients indicates that MgSO4 has no significant improvement for mortality, but there is borderline improvement in the glasgow outcome scale [50].

Conclusion

Young hydrocephalic ferrets at the age during which cerebral myelin production is just beginning did not exhibit behavioral benefits or white matter protection from MgSO4 therapy. Although MgSO4 seems to be safe in other situations, it was associated with severe sedation, which can compromise feeding. Considering the experimental and epidemiologic evidence that Mg2+ might protect the developing brain in other diseases, this negative result should not completely exclude its possible benefits in hydrocephalus. However, preclinical testing might have to be done in a larger animal model wherein continuous delivery is possible or more control can be achieved over feeding. We will continue to explore other pharmacological agents that can be used as a supplement to shunt treatment of hydrocephalus in gyrencephalic animal models.

Declarations

Authors’ contributions

DDC carried out the drug administration, behavioral work, dissections and histology, ELISAs, myelin enzyme activity assays, statistical analyses, and drafted the manuscript. DDC also assisted in the induction of hydrocephalus, MR imaging, and atomic absorption spectroscopy. ETB assisted in the induction of hydrocephalus, drug administration, behavioral work, MR imaging, and dissections. XM assisted with the MR imaging, behavioral tasks, ELISAs, myelin enzyme activity assays, and data collection. MDB conceived the study including its design and coordination, carried out the hydrocephalus induction, and guided writing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors thank Dr. Richard Buist for performing MR imaging and Dr. Douglas Goltz for supervising the magnesium ion assay.

This work was funded by Grants from the Canadian Institutes of Health Research (Grant # 109756) and from Research Manitoba to Dr. Del Bigio. Dr. Del Bigio holds the Canada Research Chair in Developmental Neuropathology. Domenico Di Curzio had a Graduate Studentship from Research Manitoba.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Human Anatomy & Cell Science, University of Manitoba
(2)
Children’s Hospital Research Institute of Manitoba
(3)
Department of Pathology, University of Manitoba Brodie 401-727 McDermot Avenue

References

  1. Del Bigio MR. Pathophysiologic consequences of hydrocephalus. Neurosurg Clin N Am. 2001;12:639–49.PubMedGoogle Scholar
  2. Del Bigio MR. Neuropathological changes caused by hydrocephalus. Acta Neuropathol (Berl). 1993;85:573–85.View ArticleGoogle Scholar
  3. Del Bigio MR. Neuropathology and structural changes in hydrocephalus. Dev Disabil Res Rev. 2010;16:16–22.View ArticlePubMedGoogle Scholar
  4. Del Bigio MR. Calcium-mediated proteolytic damage in white matter of hydrocephalic rats? J Neuropathol Exp Neurol. 2000;59:946–54.View ArticlePubMedGoogle Scholar
  5. Simpson JI, Eide TR, Schiff GA, Clagnaz JF, Hossain I, Tverskoy A, Koski G. Intrathecal magnesium sulfate protects the spinal cord from ischemic injury during thoracic aortic cross-clamping. Anesthesiology. 1994;81:1493–9.View ArticlePubMedGoogle Scholar
  6. Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anaesth. 1999;83:302–20.View ArticlePubMedGoogle Scholar
  7. de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. Physiol Rev. 2015;95:1–46.View ArticlePubMedGoogle Scholar
  8. Hilmy MI, Somjen GG. Distribution and tissue uptake of magnesium related to its pharmacological effects. Am J Physiol. 1968;214:406–13.PubMedGoogle Scholar
  9. Suzer T, Coskun E, Islekel H, Tahta K. Neuroprotective effect of magnesium on lipid peroxidation and axonal function after experimental spinal cord injury. Spinal Cord. 1999;37:480–4.View ArticlePubMedGoogle Scholar
  10. Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh RE. Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg. 1996;85:117–24.View ArticlePubMedGoogle Scholar
  11. Wolf G, Fischer S, Hass P, Abicht K, Kelhoff G. Magnesium sulphate subcutaneously injected protects against kainate-induced convulsions and neurodegeneration: in vivo study on the rat hippocampus. Neuroscience. 1991;43:31–4.View ArticlePubMedGoogle Scholar
  12. Goni-de-Cerio F, Alvarez A, Lara-Celador I, Alvarez FJ, Alonso-Alconada D, Hilario E. Magnesium sulfate treatment decreases the initial brain damage alterations produced after perinatal asphyxia in fetal lambs. J Neurosci Res. 2012;90(10):1932–40.View ArticlePubMedGoogle Scholar
  13. Sameshima H, Ikenoue T. Long-term magnesium sulfate treatment as protection against hypoxic-ischemic brain injury in seven-day-old rats. Am J Obstet Gynecol. 2001;184:185–90.View ArticlePubMedGoogle Scholar
  14. Esen F, Erdem T, Aktan D, Kalayci R, Cakar N, Kaya M, Telci L. Effects of magnesium administration on brain edema and blood-brain barrier breakdown after experimental traumatic brain injury in rats. J Neurosurg Anesthesiol. 2003;15:119–25.View ArticlePubMedGoogle Scholar
  15. Hoane MR. Assessment of cognitive function following magnesium therapy in the traumatically injured brain. Magnes Res. 2007;20:229–36.PubMedGoogle Scholar
  16. Saatman KE, Bareyre FM, Grady MS, McIntosh TK. Acute cytoskeletal alterations and cell death induced by experimental brain injury are attenuated by magnesium treatment and exacerbated by magnesium deficiency. J Neuropathol Exp Neurol. 2001;60:183–94.View ArticlePubMedGoogle Scholar
  17. McIntosh TK, Vink R, Yamakami I, Faden AI. Magnesium protects against neurological deficit after brain injury. Brain Res. 1989;482:252–60.View ArticlePubMedGoogle Scholar
  18. Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;(11):CD000025. doi:https://doi.org/10.1002/14651858.CD000025.pub2.
  19. Doyle LW, Crowther CA, Middleton P, Marret S. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet Gynecol. 2009;113:1327–33.View ArticlePubMedGoogle Scholar
  20. Nguyen TM, Crowther CA, Wilkinson D, Bain E. Magnesium sulphate for women at term for neuroprotection of the fetus. Cochrane Database Syst Rev. 2013;2:CD009395.PubMedGoogle Scholar
  21. Tagin M, Shah PS, Lee KS. Magnesium for newborns with hypoxic-ischemic encephalopathy: a systematic review and meta-analysis. J Perinatol. 2013;33:663–9.View ArticlePubMedGoogle Scholar
  22. Brewer RP, Parra A, Lynch J, Chilukuri V, Borel CO. Cerebral blood flow velocity response to magnesium sulfate in patients after subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2001;13:202–6.View ArticlePubMedGoogle Scholar
  23. Sugimoto J, Romani AM, Valentin-Torres AM, Luciano AA, Kitchen CMR, Funderburg N, Mesiano S, Bernstein HB. Magnesium decreases inflammatory cytokine production: a novel innate immunomodulatory mechanism. J Immunol. 2012;188(12):6338–46.View ArticlePubMedGoogle Scholar
  24. Del Bigio MR, Di Curzio DL. Nonsurgical therapy for hydrocephalus: a comprehensive and critical review. Fluids Barriers CNS. 2016;13:3.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Khan OH, Enno T, Del Bigio MR. Magnesium sulfate therapy is of mild benefit to young rats with kaolin-induced hydrocephalus. Pediatr Res. 2003;53:970–6.View ArticlePubMedGoogle Scholar
  26. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244–50.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Di Curzio DL, Buist RJ, Del Bigio MR. Reduced subventricular zone proliferation and white matter damage in juvenile ferrets with kaolin-induced hydrocephalus. Exp Neurol. 2013;248:112–28.View ArticlePubMedGoogle Scholar
  28. Lockard BI. The forebrain of the ferret. Lab Anim Sci. 1985;35:216–28.PubMedGoogle Scholar
  29. Hayes SG, Murray KD, Jones EG. Two epochs in the development of gamma-aminobutyric acidergic neurons in the ferret thalamus. J Comp Neurol. 2003;463:45–65.View ArticlePubMedGoogle Scholar
  30. Empie K, Rangarajan V, Juul SE. Is the ferret a suitable species for studying perinatal brain injury? Int J Dev Neurosci. 2015;45:2–10.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Christensson M, Garwicz M. Time course of postnatal motor development in ferrets: ontogenetic and comparative perspectives. Behav Brain Res. 2005;158:231–42.View ArticlePubMedGoogle Scholar
  32. Del Bigio MR, Kanfer JN, Zhang YW. Myelination delay in the cerebral white matter of immature rats with kaolin-induced hydrocephalus is reversible. J Neuropathol Exp Neurol. 1997;56:1053–66.View ArticlePubMedGoogle Scholar
  33. Kanfer JN, McCartney D. An unusual phosphodiesterase activity towards p-nitrophenylphosphorylcholine present in rat brain membranes. Neurochem Res. 1990;15:987–92.View ArticlePubMedGoogle Scholar
  34. Khan OH, McPhee LC, Moddemann LN, Del Bigio MR. Calcium antagonism in neonatal rats with kaolin-induced hydrocephalus. J Child Neurol. 2007;22:1161–6.View ArticlePubMedGoogle Scholar
  35. Koul O, Jungalwala FB. UDP-galactose: ceramide galactosyltransferase of rat central nervous system myelin during development. Neurochem Res. 1986;11:231–9.View ArticlePubMedGoogle Scholar
  36. Sok DE, Kim MR. Brain myelin-bound Zn(2+)-glycerophosphocholine cholinephosphodiesterase is a glycosylphosphatidylinositol-anchored enzyme of two different molecular forms. Neurochem Res. 1994;19:97–103.View ArticlePubMedGoogle Scholar
  37. Diaz-Arrastia R, Kochanek PM, Bergold P, Kenney K, Marx CE, Grimes CJ, Loh LT, Adam LT, Oskvig D, Curley KC, Salzer W. Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup. J Neurotrauma. 2014;31:135–58.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Rude RK, Singer FR. Magnesium deficiency and excess. Annu Rev Med. 1981;32:245–59.View ArticlePubMedGoogle Scholar
  39. McAllister JP 2nd, Miller JM. Minocycline inhibits glial proliferation in the H-Tx rat model of congenital hydrocephalus. Cerebrospinal Fluid Res. 2010;7:7.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Xu H, Tan G, Zhang S, Zhu H, Liu F, Huang C, Zhang F, Wang Z. Minocycline reduces reactive gliosis in the rat model of hydrocephalus. BMC Neurosci. 2012;13:148.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Botfield H, Gonzalez AM, Abdullah O, Skjolding AD, Berry M, McAllister JP 2nd, Logan A. Decorin prevents the development of juvenile communicating hydrocephalus. Brain. 2013;136:2842–58.View ArticlePubMedGoogle Scholar
  42. Stout C, Charles A. Modulation of intercellular calcium signaling in astrocytes by extracellular calcium and magnesium. Glia. 2003;43:265–73.View ArticlePubMedGoogle Scholar
  43. Oppelt WW, MacIntyre I, Rall DP. Magnesium exchange between blood and cerebrospinal fluid. Am J Physiol. 1963;205:959–62.PubMedGoogle Scholar
  44. Chutkow JG. Uptake of magnesium into the brain of the rat. Exp Neurol. 1978;60:592–602.View ArticlePubMedGoogle Scholar
  45. Hallak M, Berman RF, Irtenkauf SM, Evans MI, Cotton DB. Peripheral magnesium sulfate enters the brain and increases the threshold for hippocampal seizures in rats. Am J Obstet Gynecol. 1992;167:1605–10.View ArticlePubMedGoogle Scholar
  46. Hallak M. Effect of parenteral magnesium sulfate administration on excitatory amino acid receptors in the rat brain. Magnes Res. 1998;11:117–31.PubMedGoogle Scholar
  47. Orosz SE. Critical care nutrition for exotic animals. J Exotic Pet Med. 2013;22:163–77.View ArticleGoogle Scholar
  48. Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci. 2011;50:600–13.PubMedPubMed CentralGoogle Scholar
  49. Galinsky R, Bennet L, Groenendaal F, Lear CA, Tan S, van Bel F, Juul SE, Robertson NJ, Mallard C, Gunn AJ. Magnesium is not consistently neuroprotective for perinatal hypoxia-ischemia in term-equivalent models in preclinical studies: a systematic review. Dev Neurosci. 2014;36:73–82.View ArticlePubMedGoogle Scholar
  50. Li W, Bai YA, Li YJ, Liu KG, Wang MD, Xu GZ, Shang HL, Li YF. Magnesium sulfate for acute traumatic brain injury. J Craniofac Surg. 2015;26:393–8.View ArticlePubMedGoogle Scholar

Copyright

© Di Curzio et al. 2016

Advertisement